We are committed to developing and increasing access to gene therapies for patients around the world. Our mission to build a fully integrated global gene therapy company with industry-leading R&D and manufacturing.
Founded in 2019 with strong financial backing, the company has built a broad pipeline of innovative genetic medicines and fully integrated manufacturing capabilities. The management team has extensive leadership experience at leading US and Global gene and cell therapy companies across all functional areas.
The company is advancing an early to clinical-stage gene therapy pipeline with two initially focused therapeutic areas: CNS and ophthalmology. The company's vision is to develop and increase access to gene therapies for patients around the world.